Jeri R Barney JD MS Michele Antisdel MBACCRP HRPP Compliance Manager IRB Regulatory Analyst Human Research Protection Program HRPP May 16 2013 Discussion Consent Process ID: 532893
Download Presentation The PPT/PDF document "Common Problems in Informed Consent" is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
Slide1
Common Problems in Informed Consent
Jeri R.
Barney
, JD,
MS
Michele
Antisdel,
MBA/CCRP
HRPP Compliance Manager IRB Regulatory Analyst
Human Research Protection Program (HRPP)
May 16, 2013Slide2
Discussion
Consent Process
Consent Requirements
Common Problems in Informed Consent
Suggestions for ImprovementSlide3
Consent
ProcessSlide4
What is Informed Consent?
Example of Ethical Principle of Respect for Persons
Not a document, but a process
Starts at initial contact (e.g., recruitment)
Slide5
Informed Consent Process
Continues through study participation
an informed participant is better able to adhere to the protocol and therefore provide evaluable data
research staff members are obligated to share any new information related to subject’s participation (e.g., newly identified side effects, etc)Slide6
Informed Consent Process
Handing a participant the consent document and asking them to read and ask questions is NOT Informed Consent
Slide7
Consent
RequirementsSlide8
8 Basic Elements in an ICF
The following eight basic elements of informed consent are
required
to be provided in the course of the consent process. The investigator must ensure that these elements and any others required by the IRB are presented in such a manner as to facilitate the prospective participant’s ability to understand involvement in the research study.
1. Invitation to Participate
2. Risks
3. Benefits
4. Alternatives to Participation
5. Confidentiality Statement
6. Compensation
for Medical Treatment
7. Who to contact (and when) with problems/how to withdraw
8. Voluntary ParticipationSlide9
Consent Requirements
In addition to the 8 required elements, one or more of the following elements are to be provided to the subject when appropriate to the study
:
Procedures-
in lay terms! Tell which are experimental
Research not medical treatment & purpose of the research
Possibility of unforeseeable risks
The
consequences of a subject's decision to withdraw from the research and procedures for orderly termination of participation by the subject
.
A statement that significant new findings developed during the course of the research which may relate to the subject's willingness to continue participation will be provided to the subject.
How long/duration of participation
Subject responsibilities
The approximate number of subjects involved in the study
.
For FDA regulated studies: clinicaltrials.govSlide10
Regulatory Requirements
45 CFR 46.116 (HHS) and 21 CFR 50.20 (FDA) provide the general requirements for informed consent.
No investigator may involve a human being as a subject in research unless the investigator has obtained the legally effective informed consent of the subject or the subject's legally authorized representative (e.g., for a minor child this would be the parent or guardian).
An investigator shall seek such consent only under circumstances that provide the prospective subject or the representative sufficient opportunity to consider whether or not to participate and that minimize the possibility of coercion or undue influence.
The information that is given to the subject or the representative shall be in language understandable to the subject or the representative.
No informed consent, whether oral or written, may include any exculpatory language through which the subject or the representative is made to waive or appear to waive any of the subject's legal rights, or releases or appears to release the investigator, the sponsor, the institution or its agents from liability for negligence.
Slide11
Consent Requirements Continued
Documentation
of informed consent.
Informed consent
will
be documented by the use of a written consent form approved by the IRB and signed by the subject or the subject's legally authorized representative. A copy
is
given to the person signing the form
.
A consent
form may
be
either of the following
:
A
written consent
document (
consent form
or
compound consent and authorization form
)
that embodies the elements of
informed.
A
short form
written consent document stating that the elements of informed consent have been presented orally to the subject or the subject's legally authorized representative. Slide12
Consent Requirements Continued
Documentation
of informed consent.
An
IRB may waive the requirement for the investigator to obtain a signed consent form for some or all subjects if it finds either
:
(
1) That the only record linking the subject and the research would be the consent document and the principal risk would be potential harm resulting from a breach of confidentiality. Each subject will be asked whether the subject wants documentation linking the subject with the research, and the subject's wishes will govern; or
(2) That the research presents no more than minimal risk of harm to subjects and involves no procedures for which written consent is normally required outside of the research context
.
I
f the study is FDA regulated,
FDA regulations allow a waiver of informed consent only under very specific
limited circumstances (21 CFR 50.23 and 21 CFR 50.24).
In cases in which the documentation requirement is waived, the IRB may require the investigator to provide subjects with a written statement regarding the research
. The document is called an “
Information Sheet
”.Slide13
Common Problems in Informed
ConsentSlide14
Office for Human Research Protections (HRPP) Compliance Oversight Letters
OHRP reviewed 235 compliance oversight determination letters issued to 146 institutions
51% of the institutions reviewed were cited for noncompliance and deficiencies related to IRB approved informed consent documents/processes (2
nd
highest after deficiencies related to the initial IRB review process (56%))
19 determinations of noncompliance for research conducted w/o legally effective informed consentSlide15
Current FDA Statistics
Office of Scientific Investigations
Center for Drug Evaluation & Research (CDER)
(Updated: January 2013)
Source http
://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/UCM256376.pdfSlide16
Frequency
of Clinical Investigator-Related Deficiencies Based on Post-Inspection Correspondence Issued*
(CDER, FY 2012
)
*
Based on letter issue date; Inspections may have multiple deficiencies, [OSI database as of January 24, 2013]
Note that this does not denote number of inspections completed in FY 2012, but rather number of inspection reports evaluated and closed in FY2012
183 Domestic Inspections,
116 Foreign InspectionsSlide17
Frequency of Clinical Investigator Related Deficiencies Based on Post-Inspectional Correspondence Issued:
Official
Action Indicated (OAI) Final classification*
(
CDER, FY 2012)
*Based on letter issue date; Inspections may have multiple deficiencies, includes OAI untitled letters, [OSI database as of January 24, 2013]
Note
that this does not denote number of inspections completed in FY 2012, but rather number of inspection reports evaluated and closed in FY2012.
9 OAI InspectionsSlide18
Examples of Common Consent Issues
Failure to re-consent when new information becomes available
Use of expired forms or non-validated/unapproved forms
PI or consent personnel did not sign/date the form
Failure to provide copies of the forms to subjects
Providing all but the last page of the consent document to subjects
Keeping only the last page of the consent document in study filesSlide19
More Examples
Failure to obtain written informed consent (neglecting to have subjects sign a consent form)
Missing consent documents
No documentation that consent process took place and no signed consent document on
file
Use of wrong form (e.g., child signing parental permission form, patient signing
“healthy control
” form, or subject signing the wrong version)Slide20
Even More Examples
Parental
permission obtained after child assent (may suggest that study interventions took place prior to securing legally effective consent)
Enrolling non-English speaking subjects
without using a proper interpreter (e.g., using a family member or boyfriend/girlfriend to translate)
Failure
to get HIPAA
research (RAF)
signed
Changes made to the consent documents by hand AND without IRB approval (e.g., crossed out information about procedures, increased amount of payment
)Slide21
Suggestions for
ImprovementSlide22
Suggestions for Improvement
ICF Version Control Tips
Use
of expired forms or unapproved forms
Use of wrong form (child signing parental permission form or subject signing the wrong version
)
Check the Validation Box
on the last page of the consent form BEFORE you consent the subject (for paper forms). For electronic forms check the header/footer for the IRB approval. In addition; check the version date to make sure you’re using the most current copy.
Throw Out Expired or Outdated Versions
of the consent documents IMMEDIATELY. Maintain the original in the regulatory binder for the study records but any copies of expired or outdated documents should be destroyed, and electronic copies should be moved to archive folder on computer.Slide23
Suggestions for ImprovementICF Version Control Tips
Use Consent Form Log
listing the different versions, version dates, expiration dates and a brief description
For example
: Version
1: 5/2/12 Initial approval, Healthy
Control
, Healthy Control with Study Drug;
Version
2:
10/13/12
Amendment, Healthy Control
subject payment
added, Healthy Control with Study Drug
subject
payment added, study drug dosage
reduced.
Discuss New ICF Versions
at regular staff meetings to inform all personnel of changes and to ensure all staff will use the correct version. If you do not have regularly scheduled meetings, be sure to inform study personnel in other ways (e.g., via email notices).
Keep different versions in different folders
. Color code and CLEARLY label on the folder AND in the footer of the form itself.Slide24
Suggestions for Improvement
Providing Copies & Keeping Forms
Failure to provide copies of the forms to subjects
Providing all but the last page of the consent document to subjects
Keeping only the last page of the consent document in PI files
PI or consent personnel did not sign/date the form
Make a checklist
and an enrollment note template
Immediately
after signing make a copy and give the copy to subject or have subject sign duplicate copy.
Create & stick to a process
for where the signed ICF is kept (subject chart/folder, separate consent form binder)
Educate staff
so they know to provide FULL copy to subjects and keep FULL original for records
Review the signed form
for completeness BEFORE subject leaves and again BEFORE filing in your files
DO NOT
have PI pre-sign the formsSlide25
Suggestions for Improvement
Amendments & Consent Addendums
Changes made to the consent documents by hand AND without IRB approval (e.g., crossed out information about procedures, increased amount of payment)
Failure to re-consent when new information was available
Educate staff
: if changes are necessary they MUST be submitted to the IRB as an amendment and approved before implementing
Announce addendum in staff meeting or via email
Reconsent log
Check when subject’s next visit is and put a note in his/her chart and in your calendar, mark visit in red, etc.
Put copy of the addendum in the subject chart or binder prior to next visitSlide26
Suggestions for Improvement
Failure to Obtain Consent
Failure
to obtain written informed consent (forgot to have subjects sign a consent form
) or failure to have HIPAA RAF signed
Missing consent documents
No documentation that consent process took place
& no
signed consent document on
file
• Consent should be the VERY FIRST research activity (even if subjects had a form previously mailed to them) and the VERY LAST thing you do before subject leaves
• Switch
to a compound form (or staple it to the consent). REMEMBER to add the RAF to reapproved consents (RAFs don’t get approved every year)
• Use
an enrollment noteSlide27Slide28
Suggestions for ImprovementFailure to Obtain Consent
Failure to obtain written informed consent (forgot to have subjects sign a consent form) or failure to have HIPAA RAF signed
Missing consent documents
No documentation that consent process took place & no signed consent document on
file
•
Double check each other; Implement a monitoring process to check for consent forms (and other issues) on a routine
basis
•
Have
process and place for signed forms to be kept
• Ensure all study staff know where to find current forms
• Remember what hat you’re wearing Slide29
What You Can Do
Institute Processes/Form Good Habits
Consent form log
Always check the expiration dates on forms
Double check each other
Monitor your own studies on a regular basis
Talk to the staff about problem trends
Assign Responsibility
PI is ultimately responsible
One staff member responsible for consent
forms
Each staff member responsible for their own
activitiesSlide30
What You Can Do
Education
HRPP education sessions
Website policies, templates, instructions: http://www.yale.edu/hrpp/index.html
Communicate with staff (meetings or emails)
Communicate
with IRB Regularly
Ask for help
If you don’t know the answer, it’s better to ask first
Study start-up consultations
QA/QI Reviews
Call with specific questions
(203) 785-4688Slide31
Questions?
Call 203-785-4688
m
ichele.antisdel@yale.edu
jeri.barney@yale.eduSlide32
References
HRPP website:
http://www.yale.edu/hrpp/
http://www.yale.edu/hrpp/policies/index.html
http://www.yale.edu/hrpp/responsibility/compliance.html
OHRP website:
http://www.hhs.gov/ohrp/
FDA website:
http//www.fda.gov/